

North Yorkshire & York Area Prescribing Committee

Wednesday 4th October 2023
2pm – 4pm, virtual meeting via Microsoft Teams

Present

Name	Job Title	Organisation	Voting Member	Jun 2023	Jul 2023	Aug 23	Sep 2023	Oct 2023
Ken Latta	Head of Medicines Optimisation	North Yorkshire Place	Y	Y	Y	Apols	Y	Y
Dr Tim Rider	GP Prescribing Lead	North Yorkshire Place	Y	Apols	Y	Y	Y	Y
Laura Angus	Head of Medicines Optimisation and Interim Chief Pharmacist at Humber, & North Yorkshire ICS	City of York Place	Y	Y	Y (note Chris Ranson held voting rights)	Y (note Chris Ranson held voting rights)	Y (note Chris Ranson held voting rights)	From 3.25pm (note Chris Ranson held voting rights)
Dr Shaun O'Connell	GP Lead for Acute Service Transformation	City of York Place	Y	Apols	Apols	Apols	Apols	Apols
Dr William Ovenden	GP	City of York Place	Y	Y	Y	Y	Apols	Y
Kate Woodrow	Chief Pharmacist	Harrogate and District NHS Foundation Trust	Y	Sara Moore	Y	Apols	Y	Sara Moore
Dr Joanna Cunnington (from Sep 2023)	Consultant and D&T Chair	Harrogate and District NHS Foundation Trust	Y	X	X	X	Y	Y
Stuart Parkes	Chief Pharmacist	York & Scarborough Teaching Hospitals NHS Foundation Trust	Y	Y	Y	Y	Apols (note Jane Crewe held voting rights)	Y
Dr Chris Hayes	Consultant and D&T Chair	York & Scarborough Teaching Hospitals NHS Foundation Trust	Y	X	Y (from 2.40pm)	Y (from 2.25pm)	Y	X
Tracy Percival	Formulary Pharmacist	South Tees Hospitals NHS Foundation Trust	Y	Y	Apols	Y	Y	Apols
Richard Morris	Deputy Chief Pharmacist	Tees, Esk and Wear Valleys NHS Foundation Trust	Y	Apols	Apols	Chris Williams	Y	From 3.30pm
Angela Hall	Public Health representative	North Yorkshire County Council	Y	Apols	Kurt Ramsden	Kurt Ramsden	Apols	Kurt Ramsden
Alison Levin	Finance representative	North Yorkshire Place	Y	Jo Horsfall	Jo Horsfall	Jo Horsfall	Apols	Jo Horsfall
Hazel Mitford	Lay/patient representative		Y	Y	Y	Y	Y	Y
Gavin Mankin (Professional Secretary)	Principal Pharmacist Medicines Management	Regional Drug & Therapeutics Centre, Newcastle	N	Y	Y	Dan Newsome	Y	Y
Chris Ranson	Lead Medicines Management Pharmacist: Commissioning and Formulary	North Yorkshire Place	N	Y	Y	Y	Y	Y
Faisal Majothi	Medicines Optimisation Pharmacist	City of York Place	N	Y	Apols	Y	Apols	Y
Jane Crewe	Formulary Pharmacist	York & Scarborough Teaching Hospitals NHS Foundation Trust	N	Y	Y	Y	Y	Y
Sara Abbas-	Formulary Pharmacist	Harrogate and District NHS	N	Sara	Sara	Apols	Apols	Apols

Llewelyn		Foundation Trust		Abbas-Llewelyn	Abbas-Llewelyn			
Ian Dean	LPC Representative		N	Y	Apols	Y	Y	Apols
Dr Jane Raja	LMC Representative		N	Y	Y	Y	Y	Y
Sara Moore	Deputy Chief Pharmacist	Harrogate and District NHS Foundation Trust	N	See above	Apols	Y (2.15pm)	Y	Y

The meeting was quorate with xx out of 14 currently appointed voting members (or their deputies) in attendance and present throughout.

APC members and attendees were reminded to keep detailed discussions confidential to allow free and full debate to inform unencumbered decision-making. Discretion should be used when discussing meetings with non-attendees, and papers should not be shared without agreement of the chair or professional secretary, to ensure confidentiality is maintained.

The meeting was chaired by Tim Rider.

Part 1

1. Apologies for absence and quoracy check

Shaun O’Connell, Ian Dean, Tracy Percival, Kate Woodrow

The meeting was quorate.

2. Declarations of interest

Declarations of interest:

The Chair reminded subgroup members of their obligation to declare any interest they may have on any issue arising at committee meetings which might conflict with the business of the APC.

Declarations declared by members of the APC are listed in the APC’s Register of Interests. The Register is available via the professional secretary.

Declarations of interest from today’s meeting:

Nil declared.

3. Minutes of previous APC & decision summary of meeting held on 6th September 2023

The minutes of the September 2023 APC were approved as a true and accurate record.

4. Outcome of items referred to September 2023 IPMOC

TA902: Dapagliflozin for HFpEF

Considered at August APCs. Within the financial limit for Place approval. RS and KL will flag with Places dues to new financial instructions in place and await confirmation approved. Clinically supported by IPMOC.

TA906: Rimegepant for migraine

Both APCs had considered use of Rimegepant the possible spend exceeded APC sign off and Place approval was required. Adoption of NICE guidance was supported by the group mindful of a further TA for rimegepant treating migraine due in October 2023. RS and KL will flag with Places/ICB dues to new financial instructions in place and await confirmation approved.

5. Matters arising not on the agenda & declarations of AOB

AOB:

6. Action log

Semaglutide for obesity (NICE TA875)

On today’s agenda.

Formulary Updates Approved at September 2023 APC

JC/SAL have updated Y&S and Harrogate formularies. ITEM NOW CLOSED.

Outstanding actions from previous APC meetings

Diazoxide for chronic intractable hypoglycaemia

Development of shared care guideline to be presented to next APC for approval. Noted most shared care prescribing for this likely to be from HDFT.

Medical Devices Commissioning and Formulary Position

On today's agenda.

Oral minoxidil for androgenic alopecia

ICB policy alignment group have confirmed they will review this particular policy across the ICB when the NICE TA for baricitinib is published. Agreed no further action for item for APC until this policy is reviewed by the ICB.

NG18: Diabetes (type 1 and type 2) in children and young people: diagnosis and management (update) - May 2023

SP/KW have flagged NICE NG18 updates re liraglutide, dulaglutide, or empagliflozin to arrive a consensus on updating the formulary. Feedback awaited from HDFT but within YSFT would not expect to manage these patients.

IQoro® medical device

RDTG added to APC Medical Devices commissioning document to come to October 2023 APC. ITEM NOW CLOSED.

Prostate letters – Bicalutamide face to face and remote

JC to go back to urology to ask if single letter can be adopted or that secondary care initiate both the bicalutamide and the LHRH analogue. To also confirm if a two-week delay in starting bicalutamide is clinically significant and removing the word "immediately" from the letter to manage patient interactions with GP practice – *to update at next APC meeting.*

Melatonin prescribing paper

NY MO team still to complete paper to submit to future APC outlining the current issues with melatonin prescribing for consideration alongside the request to change the status.

TA902: Dapagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction.

CH still to update HF guidance to support transfer of prescribing into primary care but agreed need to wait until this TA is implemented/signed off by the ICB.

Hydroxychloroquine and chloroquine retinopathy: Recommendations on monitoring 16 December 2020 – updated RCOphth guidelines

Work on adopting national shared care template is ongoing in NY&Y.

Part 2 – Governance

7. Nil this month.

Part 3 – Mental Health

8. Nil this month.

Part 4 – Formulary issues

9. Appeals against previous APC decisions

None received.

10. Formulary NICE TAs and MHRA Drug Safety Update – August 2023

The drugs in the following TAs to be reflected in the formulary as RED drugs in the relevant chapters with links to the TAs:

- TA912: Ciplaglusidase alfa with miglustat for treating late-onset

Medicines Safety MHRA Drug Safety Update – August 2023

The group noted the drug safety updates for August 2023. The links are to be added to the relevant sections of the formulary.

ACTION:

- **JC/SAL to update the formulary websites.**

11. Other formulary issues

Lixisenatide discontinuation

Lixisenatide (Lyxumia®) 20micrograms/0.2ml solution for injection 3ml pre-filled disposable devices are being discontinued and stock will be exhausted by w/c 18th December 2023. Therefore the APC agreed to remove from formulary. Noted that impact will low as very few patients in NY&Y remain on lixisenatide.

TA 875: Semaglutide for managing overweight and obesity

NICE TA 875: Semaglutide for managing overweight and obesity was previously published in March this year but could not be approved by the APC as the drug (Wegovy®) had not been launched in the UK and therefore not available and at the time the price was not known.

There has been a further communication by the company indicating that the drug is now available in the UK and stated the following:

It will be available in specialist NHS weight management services for people who meet the National Institute for Care and Excellence (NICE) criteria or privately through a registered healthcare professional.

As we expect supply to be constrained for the foreseeable future, a proportion of available supply will be allocated for use only within the NHS to allow healthcare professionals to implement NICE guidance. We will continue to work with healthcare professionals to help ensure that patients with the highest unmet medical need are prioritised.

In North Yorkshire and York our specialist weight management services are provided by South tees and York/Scarborough hospital trust.

At present Saxenda® (Liraglutide) is available on formulary for this cohort of patients but with a slightly narrower criteria.

As Wegovy® has a confidential price attached to it, this means it will be restricted to prescribing within secondary care within these two tier 3 weight management services at this time. NHSE are planning a pilot service where the drug will be available to be prescribed within primary care by GP practices but no further details as of yet have been released.

The APC discussed the service/commissioning/service capacity implications of this NICE TA and considered the potential estimated cost impact in NY&Y. The APC agreed to recommend to IPMOC that be approved as RED drug at present because of limitations on supply and mechanism for accessing discounted price. IPMOC needs to consider the impact on current service provision and current service capacity as impact is above the level of delegated authority of the APC. Noted Trust involved yet to approve implementation of this NICE TA due to funding of drug costs and service costs.

ACTION:

- **To refer to October 2023 IPMOC as above the level of delegated authority of the APC.**

12. **New Drug Applications**

Modafinil for fatigue associated with MS

NICE NG 220 (June 2022) "Multiple sclerosis in adults: management", proposes amantadine, modafinil and SSRI as possible treatment options for the management of fatigue in multiple sclerosis (MS). On the York Formulary only amantadine is available for this indication. Indications for use for amantadine and modafinil are not specified on Harrogate's Formulary.

The APC noted the differences in opinion between clinicians in YSFY and HDFT on using modafinil for this indication. It also noted that is currently RED in Hull for this indication and AMBER SC in Leeds.

The APC noted the MHRA Drug Safety Update for modafinil which restricts its license to narcolepsy.

The discussed and agreed not in position today on the basis of the information presented to it to approved as anything other than RED as an option as per NICE guidance for fatigue associated with Multiple Sclerosis. This is an unlicensed indication and matches status in Humber. But would review this decision in light of any further information presented by the applicant.

SSRIs for fatigue associated with MS

NICE NG 220 (June 2022) "Multiple sclerosis in adults: management", proposes amantadine, modafinil and SSRI as possible treatment options for the management of fatigue in multiple sclerosis (MS). On the York Formulary only amantadine is available for this indication. Indications for use for amantadine and modafinil are not specified on Harrogate's Formulary.

The discussed and agreed to approved as an AMBER SI drug as an option as per NICE guidance for fatigue associated with Multiple Sclerosis. It noted this is an unlicensed indication but that GPs familiar with prescribing SSRIs in general.

ACTION:

- **JC/SAL to update the formulary websites.**
- **JC to take concerns around use of modafinil for this indication to applicant.**

13. **Compassionate use/free of charge scheme requests**

Nil this month.

Part 5 – Shared Care and Guidelines (non-mental health)

14. **Shared care guidelines for approval**

Azathioprine and Sirolimus shared care in renal transplant

New shared care guidelines for azathioprine and sirolimus in renal transplant were presented to and approved by the APC subject to making it clear that monitoring results should be sent to the GP via lablink. This is not a change in practice just ensure the necessary information/ paperwork is in place.

They are based on content of the National shared care for non-transplant indications.

It was agreed to keep the letter appendices as whilst not implanted in NY&Y they are the nationally agreed standard/process for transfer of shared care and as such NY&Y should be working towards implementation.

ACTION:

- **JC/SAL to update the formulary websites.**

Part 6 – Other items of business

15. **Medical devices commissioning position**

A full review of previous Y&S Medical Devices Commissioning Position document has been carried out and updated for NY&Y. The updated version was approved by the APC.

ACTION:

- **JC/SAL to update the formulary websites.**

16. Shingles vaccine – updated guidelines in Green Book from Sept 2023

An update and change to the Green Book on shingles vaccine from September 2023 was shared with the APC for information.

The APC noted that shingles vaccine is NHSE commissioned, and the change has been/is being promoted to primary care by them. GP systems are setup to identify eligible patients.

17. Antenatal anaemia management plan HDFT

There has been a change to the HDFT antenatal anaemia management plan in accordance with recommendations from the British Journal of Haematology. Lower doses of oral iron supplements (optimal elemental oral iron 40-80mg every morning) which reduces adverse outcomes including blood transfusions and need for IV iron.

Formulary choice at HDFT is currently ferrous fumarate 322mg tablets (100mg elemental iron).

The proposed switch to ferrous fumarate 210mg tablets 1 daily or sodium feredetate liquid 10ml daily 1 hour before food or medicines to aid absorption was approved by the APC.

ACTION:

- **JC/SAL to update the formulary websites.**

Part 7 – Standing items (for information only)

18. IPMOC minutes – July 2023

Not yet available.

19. TEWV D&T minutes – March 2023

Not yet available.

20. York & Scarborough Trust Drug and Therapeutics Committee minutes – July 2023

Circulated for information.

21. Harrogate Trust Medicines and Therapeutics Group minutes – since September 2022

Not yet available.

22. West Yorkshire ICS APC Minutes – since March 2023

Not yet available.

23. Humber APC minutes – September 2023

Circulated for information.

24. Humber APC decisions & recommendations – September 2023

Circulated for information.

25. RDTC Monthly Horizon scanning – September 2023

Circulated for information.

26. NENC Medicines Committee decision Summary – August 2023

Not yet available.

Any Other Business

ADHD drug current supply issues

The APC discussed the current ADHD drug supply issues at the associated national patient safety alert issued at the end of September 2023.

The drug of most concern is guanfacine as requires dose tapering prior to stopping.

Discussed that situation is likely to change rapidly so suggest deal with each individual patient as they present but that a more proactive review of patients on guanfacine may be required.

Agreed that NY&Y MO Team would work with TEWV on some comms to go out to primary care in NY&Y by the end of the of the week.

ACTION:

- **NY&Y MO Team to work with TEWV on some comms to go out to primary care in NY&Y by the end of week ending 6th October 2023.**

Date and time of next meeting

Wednesday 6th December 2023, 2pm – 4.30pm, virtual meeting via Microsoft Teams
(meeting scheduled for 1st November 2023 cancelled)